EKOS Corporation, a BTG International group company (BTG plc (LSE: BTG)), notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States. The…
SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE
Monday, March 31, 2014
SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment